PDCD1 and endometrial cancer: Studies that included less than 100 patients with metastatic or advanced endometrial cancer, mainly assessing PD-L1 inhibitors impact; and those with more than 100 patients, focused on PD-1 inhibitor large evaluations (Table 1).